lead compound

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

A unique collection of 3660 drugs with anti-cancer activity or potential anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 535 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.

A unique collection of 573 cancer cell differentiation inducing compounds for high throughput and high content screening;

A unique collection of 2440 compounds with anti-breast cancer therapeutic activity or targeting breast cancer's major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study;

A unique collection of 2508 pancreatic cancer related compounds can be used in HTS and HCS;

1880 compounds associated with colorectal cancer that can be used for high-throughput and high-content screening.

2256 compounds associated with prostate cancer that can be used for high-throughput and high-content screening.

A unique collection of 1120 bioactive small molecules with neuroprotective relevance for high throughput screening (HTS) and high content screening (HCS);

A collection of 27752 bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

600 well-chosen unique anti-parasitic small molecules;

A unique collection of 1600 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

609 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.

A unique collection of 1544 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1793 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2450 anti-obesity compounds for high throughput and high content screening;

A unique collection of 2405 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 857 compounds with anti-PD activities or acting on main drug targets of PD can be used for HTS and HCS.

1163 compounds associated with depression that can be used for high-throughput and high-content screening

Well-chosen 1360 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 950 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 4221 natural products for high throughput screening (HTS) and high content screening (HCS);

For your convenience, there are Diversity Sets of 5,000, 10,000, 15,000, and 20,000 compounds with no structure overlap.

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.